BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33706048)

  • 1. Impact of the weekday of the first intensity-modulated radiotherapy treatment on the survival outcomes of patients with nasopharyngeal carcinoma: A multicenter cohort study.
    Mo Y; Zhang B; Pan Y; Qin Q; Ye Y; Li X; Huang L; Jiang W
    Oral Oncol; 2021 May; 116():105258. PubMed ID: 33706048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superiority of intensity-modulated radiation therapy in nasopharyngeal carcinoma with skull-base invasion.
    Liao S; Xie Y; Feng Y; Zhou Y; Pan Y; Fan J; Mi J; Qin X; Yao D; Jiang W
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):429-439. PubMed ID: 31677113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Geographical disparities in the prognosis of patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy: a large institution-based cohort study from an endemic area.
    Lin ST; Meng DF; Yang Q; Wang W; Peng LX; Zheng LS; Qiang YY; Mei Y; Xu L; Li CZ; Peng XS; Hu H; Lang YH; Liu ZJ; Wang MD; Li HF; Huang BJ; Qian CN; Sun R
    BMJ Open; 2020 Nov; 10(11):e037150. PubMed ID: 33172940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of intensity-modulated radiation therapy alone vs. intensity-modulated radiation therapy combined with chemotherapy in elderly nasopharyngeal carcinoma patients (aged >65 years).
    Mi JL; Meng YL; Wu HL; Cao YL; Zhang B; Pan YF; Zhou YY; Fan JF; Liao SF; Qin XL; Yao DC; Jiang W
    Strahlenther Onkol; 2020 Mar; 196(3):270-279. PubMed ID: 31748837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined prognostic value of pretreatment anemia and cervical node necrosis in patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: A large-scale retrospective study.
    Zhang LL; Zhou GQ; Li YY; Tang LL; Mao YP; Lin AH; Ma J; Qi ZY; Sun Y
    Cancer Med; 2017 Dec; 6(12):2822-2831. PubMed ID: 29034992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-treatment serum lactic dehydrogenase as a predictive indicator for distant metastasis and survival of patients with nasopharyngeal carcinoma.
    Wang J; Li L; Dong BQ; Xu YJ; Zheng YD; Sun ZW; Yang Y; Chen YY; Chen XZ; Chen M
    Oncotarget; 2016 May; 7(19):27458-67. PubMed ID: 27050275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival impact of radiotherapy interruption in nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis.
    Yao JJ; Zhang F; Gao TS; Zhang WJ; Lawrence WR; Zhu BT; Zhou GQ; Ma J; Wang SY; Sun Y
    Radiother Oncol; 2019 Mar; 132():178-187. PubMed ID: 30448002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the seventh and eighth editions of the UICC/AJCC staging system for nasopharyngeal carcinoma: analysis of 1317 patients treated with intensity-modulated radiotherapy at two centers.
    Yang XL; Wang Y; Liang SB; He SS; Chen DM; Chen HY; Lu LX; Chen Y
    BMC Cancer; 2018 May; 18(1):606. PubMed ID: 29843648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: A 10-year experience with a large cohort and long follow-up.
    Zhang MX; Li J; Shen GP; Zou X; Xu JJ; Jiang R; You R; Hua YJ; Sun Y; Ma J; Hong MH; Chen MY
    Eur J Cancer; 2015 Nov; 51(17):2587-95. PubMed ID: 26318726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma.
    Aftab O; Liao S; Zhang R; Tang N; Luo M; Zhang B; Shahi S; Rai R; Ali J; Jiang W
    Radiat Oncol; 2020 Mar; 15(1):66. PubMed ID: 32178698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
    Liang SB; Zhang N; Chen DM; Yang XL; Chen BH; Zhao H; Lu RL; Chen Y; Fu LW
    Radiother Oncol; 2019 Mar; 132():223-229. PubMed ID: 30366725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of adaptive replanning in patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiotherapy: a propensity score matched analysis.
    Luo Y; Qin Y; Lang J
    Clin Transl Oncol; 2017 Apr; 19(4):470-476. PubMed ID: 27718153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment prognostic factors of survival and late toxicities for patients with nasopharyngeal carcinoma treated by simultaneous integrated boost intensity-modulated radiotherapy.
    Lin YH; Huang TL; Chien CY; Chen HC; Hsu HC; Huang EY; Wang CJ; Huang YJ; Wang YM; Huang CC; Chou SY; Liao KC; Fang FM
    Radiat Oncol; 2018 Mar; 13(1):45. PubMed ID: 29554940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Characteristics and Survival Outcomes in Patients Aged 70 Years and Older with Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy Era.
    Jin YN; Zhang WJ; Cai XY; Li MS; Lawrence WR; Wang SY; Mai DM; Du YY; Luo DH; Mo HY
    Cancer Res Treat; 2019 Jan; 51(1):34-42. PubMed ID: 29409313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective study comparing the outcomes and toxicities of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy for the treatment of children and adolescent nasopharyngeal carcinoma.
    Qiu WZ; Peng XS; Xia HQ; Huang PY; Guo X; Cao KJ
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1563-1572. PubMed ID: 28342002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: clinical outcomes and patterns of failure among subsets of 8th AJCC stage IVa.
    Huang CL; Guo R; Li JY; Xu C; Mao YP; Tian L; Lin AH; Sun Y; Ma J; Tang LL
    Eur Radiol; 2020 Feb; 30(2):816-822. PubMed ID: 31650266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Validation of Web-Based Nomograms to Precisely Predict Survival Outcomes of Non-metastatic Nasopharyngeal Carcinoma in an Endemic Area.
    Yao JJ; Lin L; Gao TS; Zhang WJ; Lawrence WR; Ma J; Sun Y
    Cancer Res Treat; 2021 Jul; 53(3):657-670. PubMed ID: 33285052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic value of weight loss during radiotherapy among patients with nasopharyngeal carcinoma: a large-scale cohort study.
    Jin YN; Xia TL; Mai DM; Yao JJ; Jiang C; He WZ; Xia LP
    BMC Cancer; 2022 May; 22(1):505. PubMed ID: 35524225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A large cohort study reveals the association of elevated peripheral blood lymphocyte-to-monocyte ratio with favorable prognosis in nasopharyngeal carcinoma.
    Li J; Jiang R; Liu WS; Liu Q; Xu M; Feng QS; Chen LZ; Bei JX; Chen MY; Zeng YX
    PLoS One; 2013; 8(12):e83069. PubMed ID: 24386144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
    Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.